Hopefully your assumption, as you concluded, will turn out incorrect.
I don't care much about precedent cases (e.g. historical SP have as a maximum tripled). If everything turns out as expected there has never been a drug like this before. My experience is very limited, but I couldn't fathom that a bidding war turns out only like this: partner up for some chump change (e.g. pay a few trials and running costs) and then have the monopoly privilege to sit alone at the buyout table. Please read Gemini's answer to three questions considering only the cold/hot MoA below. If that's worth only $35B (without any other indications) in a bidding war hopefully featuring Merck and Pfizer, logics officially can be declared dead and our negotiatior(s) will have failed miserabley. As Jake wrote, we won't get to see that match, but it would still be a defeat, televised or not. This isn't charity, whoever buys us will literally print money and a mab like this won't be copied within months after a CCR5 hype would ignite. Maraviroc has awful side effects, lacks full receptor occupancy and doesn't come close to Leronlimab. Now "making" something similar to Leronlimab will take thousands and probably way more iterations, and all those would have to go through the regulatory/trials process. So that threat is miniscule/inexistent. Before that our exclusivity protection would expire. If a true bidding war ends below $60B the bidders don't grasp the true value. Cytodyn should just sit silently at the negotiation and watch them eat each other alive. But the trials have to confirm first.
According to Gemini:
"Almost all "Hot" tumors (~25% of total) are CCR5-positive because they require the CCR5 axis to bring in the T-cells that make them hot. But only about 13-20% of all those treated patients show a durable response.
However, having CCR5 does not automatically make a tumor "hot." Many "cold" tumors (the other ~75%) also express CCR5, but they use it to build a "shield" of immunosuppressive cells or to drive their own growth.
The ~20% durable response rate represents the "perfect storm" where the tumor is hot, reachable, and hasn't yet evolved a workaround.
If the clinical data and the specific Mechanism of Action (MoA) published by CytoDyn are confirmed in larger prospective trials, the theoretical improvement to the current 20% durable response rate (DRR) for checkpoint inhibitors (ICIs) could be substantial, potentially moving the needle from a "minority benefit" to a "majority backbone" therapy.
Based on the publications and the most recent data (presented at ESMO and SABCS 2025), here is how the 20% DRR could theoretically be improved:
1. The "Conversion" Factor (88% Induction)
The most critical data point from recent CytoDyn publications is the PD-L1 induction rate.
* The Problem: Currently, ICIs only work well in patients who are "PD-L1 positive." In aggressive tumors like metastatic TNBC or MSS Colorectal cancer, a large majority of patients are PD-L1 negative or "cold."
* The Leronlimab Effect: CytoDyn’s retrospective analysis of 28 mTNBC patients showed that leronlimab (at doses >525mg) induced PD-L1 expression on circulating tumor cells in 88% of patients.
* Theoretical Impact: If 88% of "cold" (non-eligible or non-responding) tumors can be converted to "hot" (PD-L1 positive) status, the pool of potential responders expands from the current ~25% (naturally hot) to over 80% of the total population.
2. The "Synergy" Data (The 100% Subgroup)
While the overall survival for the entire group of heavily pre-treated patients in their pooled analysis was 17.9% at 5 years, a specific subgroup showed extraordinary results:
* The Findings: In the subset of patients who showed PD-L1 induction after leronlimab and subsequently received an ICI, 5 out of 5 (100%) were still alive after a median of ~60 months. * Theoretical Improvement: If this 100% response rate in "primed" patients holds true in larger groups, the durable response rate could theoretically move from 20% toward 60-70% for CCR5+ tumors. This assumes that the "priming" makes the ICI as effective as it is in naturally "hot" tumors like melanoma.
3. Overcoming the "Cold" Barriers
Leronlimab’s MoA targets three specific barriers that currently keep the response rate at 20%:
* Macrophage Repolarization: It shifts immunosuppressive M2 macrophages (which shield the tumor) to pro-inflammatory M1 macrophages (which attack it).
* Treg/MDSC Blockade: By blocking CCR5, it theoretically prevents the recruitment of "suppressor" cells that act as bodyguards for the tumor.
* Anti-Metastatic Effect: Publications show a 98% reduction in breast cancer metastasis in animal models, suggesting that even if a response isn't "complete," the disease may be stabilized into a manageable chronic condition.
4. Summary: The Theoretical Ceiling
If we apply the "Leronlimab MoA" to the global solid tumor landscape:
| Metric | Current ICI Status | Theoretical with Leronlimab Priming |
|---|---|---|
| Eligible Population | ~45% (PD-L1+) | ~90% (Induced PD-L1) |
| Initial Response Rate | ~15–25% | ~50–60% |
| Durable Response (5yr) | ~20% | ~45–55% |
Conclusion
Theoretically, confirming Leronlimab’s MoA could more than double the durable response rate (from ~20% to ~50%+). By "unmasking" the 70% of tumors that are currently "cold" but express CCR5 (which is up to 95% in some cancers), the therapy would essentially remove the tumor's invisibility cloak, allowing the immune system to do the work it is already capable of doing.
Caveat: It is important to note that the 100% survival rate (5/5) is a very small sample size from retrospective/compassionate use data. The upcoming Phase 2 prospective trials in mCRC and PD-L1-negative mTNBC will be the definitive test of whether this theoretical improvement translates to the broader cancer population.
Based on the data from CytoDyn's recent publications, here is how those metrics would theoretically be transformed if leronlimab were confirmed as a universal "priming" agent for checkpoint inhibitors (ICIs):
1. Improvement in ICI Eligibility (PD-L1 Expression)
Currently, only about 55% of metastatic solid tumor patients meet the criteria for ICI treatment (typically based on being PD-L1 positive or having high mutation counts).
* The Leronlimab Impact: CytoDyn’s findings show that leronlimab induced PD-L1 expression in 88% of patients with metastatic triple-negative breast cancer (mTNBC) who were previously PD-L1 negative.
* The Potential Result: If this 88% conversion rate is applied to the 45% of patients currently considered "ineligible" (cold tumors), an additional ~40% of the total cancer population would become eligible.
* New Baseline: Total ICI eligibility could potentially reach ~95% of all metastatic solid tumor patients.
2. Outcome for Durable Response Rate (DRR)
The current 20% durable response rate is a "diluted" number because it includes many patients who only respond briefly or not at all.
* The Findings: In a specific subgroup of "primed" patients (those who showed leronlimab-induced PD-L1 and then received an ICI), the survival rate was 100% (5 out of 5 patients) after a median follow-up of approximately 60 months.
* The Potential Result: If "priming" with leronlimab makes induced tumors behave like the most responsive "hot" tumors, the overall durable response rate could theoretically move from 20% to 60%.
* Impact: This would represent a 3x increase in the number of patients achieving long-term, life-saving benefits from immunotherapy.
3. Potential Cancer Market Growth Factor
The global ICI market is currently valued at approximately $60 billion, serving the ~20% of the initial patients of the smaller pool who respond well.
* Volume Increase: Expanding eligibility from 55% to 95% represents a 1.7x increase in the patient pool.
* Duration Multiplier: Because durable responders stay on therapy significantly longer (often 2+ years vs. 3 months for non-responders), tripling the number of responders (from 20% to 60%) has a massive compounding effect on revenue.
* Market Growth Factor: When combining the larger patient pool, the tripled response rate, and the "combination premium" (paying for both an ICI and leronlimab), the total ICI market could grow by a factor of at least 4x.
* Total Market Size: This would move the global ICI market from its current ~$60 billion toward ~$240 billion annually.
Summary: In this scenario, leronlimab would effectively act as the "key" that unlocks the remaining 75–80% of the solid tumor market, turning checkpoint inhibitors from a specialized treatment into the near-universal standard of care for cancer."
I don't care much about precedent cases (e.g. historical SP have as a maximum tripled). If everything turns out as expected there has never been a drug like this before. My experience is very limited, but I couldn't fathom that a bidding war turns out only like this: partner up for some chump change (e.g. pay a few trials and running costs) and then have the monopoly privilege to sit alone at the buyout table. Please read Gemini's answer to three questions considering only the cold/hot MoA below. If that's worth only $35B (without any other indications) in a bidding war hopefully featuring Merck and Pfizer, logics officially can be declared dead and our negotiatior(s) will have failed miserabley. As Jake wrote, we won't get to see that match, but it would still be a defeat, televised or not. This isn't charity, whoever buys us will literally print money and a mab like this won't be copied within months after a CCR5 hype would ignite. Maraviroc has awful side effects, lacks full receptor occupancy and doesn't come close to Leronlimab. Now "making" something similar to Leronlimab will take thousands and probably way more iterations, and all those would have to go through the regulatory/trials process. So that threat is miniscule/inexistent. Before that our exclusivity protection would expire. If a true bidding war ends below $60B the bidders don't grasp the true value. Cytodyn should just sit silently at the negotiation and watch them eat each other alive. But the trials have to confirm first.
According to Gemini:
"Almost all "Hot" tumors (~25% of total) are CCR5-positive because they require the CCR5 axis to bring in the T-cells that make them hot. But only about 13-20% of all those treated patients show a durable response.
However, having CCR5 does not automatically make a tumor "hot." Many "cold" tumors (the other ~75%) also express CCR5, but they use it to build a "shield" of immunosuppressive cells or to drive their own growth.
The ~20% durable response rate represents the "perfect storm" where the tumor is hot, reachable, and hasn't yet evolved a workaround.
If the clinical data and the specific Mechanism of Action (MoA) published by CytoDyn are confirmed in larger prospective trials, the theoretical improvement to the current 20% durable response rate (DRR) for checkpoint inhibitors (ICIs) could be substantial, potentially moving the needle from a "minority benefit" to a "majority backbone" therapy.
Based on the publications and the most recent data (presented at ESMO and SABCS 2025), here is how the 20% DRR could theoretically be improved:
1. The "Conversion" Factor (88% Induction)
The most critical data point from recent CytoDyn publications is the PD-L1 induction rate.
* The Problem: Currently, ICIs only work well in patients who are "PD-L1 positive." In aggressive tumors like metastatic TNBC or MSS Colorectal cancer, a large majority of patients are PD-L1 negative or "cold."
* The Leronlimab Effect: CytoDyn’s retrospective analysis of 28 mTNBC patients showed that leronlimab (at doses >525mg) induced PD-L1 expression on circulating tumor cells in 88% of patients.
* Theoretical Impact: If 88% of "cold" (non-eligible or non-responding) tumors can be converted to "hot" (PD-L1 positive) status, the pool of potential responders expands from the current ~25% (naturally hot) to over 80% of the total population.
2. The "Synergy" Data (The 100% Subgroup)
While the overall survival for the entire group of heavily pre-treated patients in their pooled analysis was 17.9% at 5 years, a specific subgroup showed extraordinary results:
* The Findings: In the subset of patients who showed PD-L1 induction after leronlimab and subsequently received an ICI, 5 out of 5 (100%) were still alive after a median of ~60 months. * Theoretical Improvement: If this 100% response rate in "primed" patients holds true in larger groups, the durable response rate could theoretically move from 20% toward 60-70% for CCR5+ tumors. This assumes that the "priming" makes the ICI as effective as it is in naturally "hot" tumors like melanoma.
3. Overcoming the "Cold" Barriers
Leronlimab’s MoA targets three specific barriers that currently keep the response rate at 20%:
* Macrophage Repolarization: It shifts immunosuppressive M2 macrophages (which shield the tumor) to pro-inflammatory M1 macrophages (which attack it).
* Treg/MDSC Blockade: By blocking CCR5, it theoretically prevents the recruitment of "suppressor" cells that act as bodyguards for the tumor.
* Anti-Metastatic Effect: Publications show a 98% reduction in breast cancer metastasis in animal models, suggesting that even if a response isn't "complete," the disease may be stabilized into a manageable chronic condition.
4. Summary: The Theoretical Ceiling
If we apply the "Leronlimab MoA" to the global solid tumor landscape:
| Metric | Current ICI Status | Theoretical with Leronlimab Priming |
|---|---|---|
| Eligible Population | ~45% (PD-L1+) | ~90% (Induced PD-L1) |
| Initial Response Rate | ~15–25% | ~50–60% |
| Durable Response (5yr) | ~20% | ~45–55% |
Conclusion
Theoretically, confirming Leronlimab’s MoA could more than double the durable response rate (from ~20% to ~50%+). By "unmasking" the 70% of tumors that are currently "cold" but express CCR5 (which is up to 95% in some cancers), the therapy would essentially remove the tumor's invisibility cloak, allowing the immune system to do the work it is already capable of doing.
Caveat: It is important to note that the 100% survival rate (5/5) is a very small sample size from retrospective/compassionate use data. The upcoming Phase 2 prospective trials in mCRC and PD-L1-negative mTNBC will be the definitive test of whether this theoretical improvement translates to the broader cancer population.
Based on the data from CytoDyn's recent publications, here is how those metrics would theoretically be transformed if leronlimab were confirmed as a universal "priming" agent for checkpoint inhibitors (ICIs):
1. Improvement in ICI Eligibility (PD-L1 Expression)
Currently, only about 55% of metastatic solid tumor patients meet the criteria for ICI treatment (typically based on being PD-L1 positive or having high mutation counts).
* The Leronlimab Impact: CytoDyn’s findings show that leronlimab induced PD-L1 expression in 88% of patients with metastatic triple-negative breast cancer (mTNBC) who were previously PD-L1 negative.
* The Potential Result: If this 88% conversion rate is applied to the 45% of patients currently considered "ineligible" (cold tumors), an additional ~40% of the total cancer population would become eligible.
* New Baseline: Total ICI eligibility could potentially reach ~95% of all metastatic solid tumor patients.
2. Outcome for Durable Response Rate (DRR)
The current 20% durable response rate is a "diluted" number because it includes many patients who only respond briefly or not at all.
* The Findings: In a specific subgroup of "primed" patients (those who showed leronlimab-induced PD-L1 and then received an ICI), the survival rate was 100% (5 out of 5 patients) after a median follow-up of approximately 60 months.
* The Potential Result: If "priming" with leronlimab makes induced tumors behave like the most responsive "hot" tumors, the overall durable response rate could theoretically move from 20% to 60%.
* Impact: This would represent a 3x increase in the number of patients achieving long-term, life-saving benefits from immunotherapy.
3. Potential Cancer Market Growth Factor
The global ICI market is currently valued at approximately $60 billion, serving the ~20% of the initial patients of the smaller pool who respond well.
* Volume Increase: Expanding eligibility from 55% to 95% represents a 1.7x increase in the patient pool.
* Duration Multiplier: Because durable responders stay on therapy significantly longer (often 2+ years vs. 3 months for non-responders), tripling the number of responders (from 20% to 60%) has a massive compounding effect on revenue.
* Market Growth Factor: When combining the larger patient pool, the tripled response rate, and the "combination premium" (paying for both an ICI and leronlimab), the total ICI market could grow by a factor of at least 4x.
* Total Market Size: This would move the global ICI market from its current ~$60 billion toward ~$240 billion annually.
Summary: In this scenario, leronlimab would effectively act as the "key" that unlocks the remaining 75–80% of the solid tumor market, turning checkpoint inhibitors from a specialized treatment into the near-universal standard of care for cancer."
11
